| REVIEW |
|
|
|
|
|
Δ 9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity |
| Swapnali Chetia, Gaurab Borah |
| Department of Zoology, Rajiv Gandhi University, Rono Hills, Doimukh, Arunachal Pradesh 791112, India |
|
|
|
|
Abstract Δ9-tetrahydrocannabinol (THC) of cannabis is the main psychoactive component which is a global significant concern to human health. Evaluation on THC reported its drastic effect on the brain dopaminergic (DAergic) system stimulating mesolimbic DA containing neurons thereby increasing the level of striatal DA. Cannabidiol (CBD), with its anxiolytic and anti-psychotic property, is potent to ameliorate the THC-induced DAergic variations. Legal authorization of cannabis use and its analogs in most countries led to a drastic dispute in the elicitation of cannabis products. With a recent increase in cannabis-induced disorder rates, the present review highlighted the detrimental effects of THC and the effects of CBD on THC induced alterations in DA synthesis and release. Alongside the reported data, uses of cannabis as a therapeutic medium in a number of health complications are also being briefly reviewed. These evaluated reports led to an anticipation of additional research contradictory to the findings of THC and CBD activity in the brain DAergic system and their medical implementations as therapeutics.
|
| Keywords
Cannabis
Tetrahydrocannabinol
Cannabidiol
Dopamine
Medicinal uses
|
| Fund:The authors sincerely acknowledge the funding (Sanction Order No. DST/Inspire Fellowship/2016/ IF160620) dated 01-22-2020 and support provided by the Department of Science and Technology, Govt. of India and University Grants Commission, New Delhi. |
|
Corresponding Authors:
Swapnali Chetia
E-mail: swapnali.chetia@rgu.ac.in,swapnalimann@gmail.com
|
|
Issue Date: 23 October 2020
|
|
|
1. G. Thomas, R.A. Kloner, S. Rezkalla, Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation:what cardiologists need to know. Am. J. Cardiol. 133, 187-190 (2014)
2. V. Wolff, E. Jouanjus, Strokes are possible complications of cannabinoids use. Epilepsy Behav. 70, 356-363 (2017)
3. United Nations Office on Drugs and Crime (UNODC), Cannabis and hallucinogens, World Drug Rep. 2019. p. 1-71.
4. T.C. Ford, A.C. Hayley, L.A. Downey, A.C. Parrott, Cannabis:an overview of its adverse acute and chronic effects and its implications. Curr. Drug Abuse Rev. 10, 6-8 (2017)
5. L. Karila, P. Roux, B. Rolland, A. Benyamina, M. Reynaud, H.J. Aubin, C. Lancon, Acute and long term effects of cannabis use:a review. Curr. Pharm. Des. 20, 4112-4118 (2014)
6. C.M. Milroy, J.L. Parai, The histopathology of drugs of abuse. Histopathology 59, 579-593 (2011)
7. B.R. Thanvi, S.D. Treadwell, Cannabis and Stroke:is there a link? Postgrad. Med. J. 85, 80-83 (2009)
8. B. Chadwick, M.L. Miller, Y.L. Hurd, Cannabis use during adolescent development:susceptibility to psychiatric illness. Front. Psychiatry. 4, 129 (2013)
9. G. Battistella, E. Fornari, J.M. Annoni, M. Chtioui, K. Dao, M. Fabritius, B. Favrat, J.F. Mall, P. Maeder, C. Giroud, Long term effects of cannabis on brain structure. Neuropsychopharmacology. 39, 2041-2048 (2014)
10. S.J. Broyd, H.H. Van Hell, C. Beale, M. Yueel, N. Solouiji, Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol. Psychiatry. 79, 57-567 (2016)
11. H. Szutorisz, Y.L. Hurd, High times for cannabis:epigenetic imprint and its legacy on brain and behavior. Neurosci. Biobehav. Rev. 85, 93-101 (2018)
12. S. Chandra, M.M. Radwan, C.G. Majumdar, J.C. Church, T.P. Freeman, M.A. ElSohly, New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur. Arch. Psychiatry Clin. Neurosci. 269, 5-15 (2019)
13. Z. Atakan, Cannabis, a complex plant:different compounds and different effects on individuals. Ther. Adv. Psychopharmacol. 2, 241-254 (2012)
14. T.A. Iseger, M.G. Bossong, A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Res. 162, 1-3 (2015)
15. A. Batalla, J.A. Crippa, G.F. Busatto, F.S. Guimarae, A.W. Zuardi, O. Valverde, Z. Atakan, P.K. McGuire, S. Bhattacharyya, R. Martin-Santos, Neuroimaging studies of acute effects of THC and CBD in humans and animals:a systematic review. Curr. Pharm. Des. 20, 2168-2185 (2014)
16. T.P. Freeman, C. Hindocha, S.F. Green, M.A.P. Bloomfield, Medical use of cannabis based products and cannabinoids. BMJ 365, 1-7 (2019)
17. J.M.N.C. Ton, G.A. Gerhardt, M. Friedemann, A.M. Etgen, G.M. Rose, N.S. Sharpless, E.L. Gardner, The effects of delta 9 tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus:an in vivo electrochemical and in vivo microdialysis study. Brain Res. 451, 59-68 (1988)
18. P.R.A. Stokes, A. Egerton, B. Watson, A. Reid, G. Breen, A. Lingford-Hughes, D.J. Nutt, M.A. Mehta, Significant decreases in frontal and temporal[11C]-raclopride binding after THC challenge. NeuroImage. 52, 1521-1527 (2010)
19. M.G. Bossong, M.A. Mehta, B.N.M. VanBerckel, O.D. Howes, R.S. Kahn, P.R.A. Stokes, Further human evidence for striatal dopamine release induced by administration of δ9-tetrahydrocannabinol (THC):selectivity to limbic striatum. Psychopharmacology 232, 2723-2729 (2015)
20. M.A.P. Bloomfield, A.H. Ashok, N.D. Volkow, O.D. Howes, The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature 539, 369-377 (2016)
21. G.F. Koob, N.D. Volkow, Neurobiology of addiction:a neurocircuitry analysis. Lancet Psychiatry. 3, 760-773 (2016)
22. P. Trifilieff, D. Martinez, Imaging addiction:D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. Neuropharmacol. 76, 498-509 (2014)
23. N.D. Volkow, J.S. Fowler, G.J. Wang, R. Baler, F. Telang, Imaging dopamine's role in drug abuse and addiction. Neuropharmacol. 56, 3-8 (2009)
24. M.A. Bloomfield, C.J. Morgan, A. Egerton, S. Kapur, H.V. Curran, O.D. Howes, Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol. Psychiatry. 75, 470-478 (2014)
25. R. Mizrahi, M. Kenk, I. Suridjan, I. Boileau, T.P. George, K. McKenzie, A.A. Wilson, S. Houle, P. Rusjan, Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacol 39, 1479-1489 (2014)
26. D.M. Dougherty, C.W. Mathias, M.A. Dawes, R.M. Furr, N.E. Charles, A. Liguori, E.E. Shannon, A. Acheson, Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacol. 226, 307-319 (2013)
27. S.M. Landau, R. Lal, J.P. O'Neil, S. Baker, W.J. Jagust, Striatal dopamine and working memory. Cereb. Cortex. 19, 445-454 (2009)
28. L. Wilkinson, Y.F. Tai, C.S. Lin, D.A. Lagnado, D.J. Brooks, P. Piccini, M. Jahanshahi, Probabilistic classification learning with corrective feedback is associated with in vivo striatal dopamine release in the ventral striatum, while learning without feedback is not. Hum. Brain Mapp. 35, 5106-5115 (2014)
29. E. van de Giessen, J.J. Weinstein, C.M. Cassidy, M. Haney, Z. Dong, R. Ghazzaoui, N. Ojeil, L.S. Kegeles, X. Xu, N.P. Vadhan, N.D. Volkow, M. Slifstein, A. Abi-Dargham, Deficits in striatal dopamine release in cannabis dependence. Mol. Psychiatry. 22, 68-75 (2017)
30. C. de la Fuente-Sandoval, P. Leon-Ortiz, R. Favila, S. Stephano, D. Mamo, J. Ramirez-Bermudez, A.G. Guerrero, Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacol 36, 1781-1791 (2011)
31. N.V. Kraguljac, D.M. White, M.A. Reid, A.C. Lahti, Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry. 70, 1294-1302 (2013)
32. D.M. Semple, A.M. McIntosh, S.M. Lawrie, Cannabis as a risk factor for psychosis:systematic review. J. Psychopharmacol. 19, 187-194 (2005)
33. J. Ceccarini, M. De Hert, R. Van Winkel, J. Peuskens, G. Bormans, L. Kranaster, F. Enning, D. Koethe, F.M. Leweke, K.V. Laere, Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. NeuroImage. 79, 304-312 (2013)
34. A.B. Martin, E. Fernandez-Espejo, B. Ferrer, M.A. Gorriti, A. Bilbao, M. Navarro, F.R. de Fonseca, R.R. Moratalla, Expression and function of CB1 receptor in the rat striatum:localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacol 33, 1667-1679 (2008)
35. V. Van Waes, J.A. Beverley, H. Siman, K.Y. Tseng, H. Steiner, CB1 Cannabinoid receptor expression in the striatum:association with corticostriatal circuits and developmental regulation. Front. Pharmacol. 3, 21 (2012)
36. M. Herkenham, A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, B.R. de Costa, K.C. Rice, Cannabinoid receptor localization in brain. Proceed. Nat. Acad. Sci. U. S. A. 87, 1932-1936 (1990)
37. C.C. Felder, J.S. Veluz, H.L. Williams, E.M. Briley, L.A. Matsuda, Cannabinoid agonists stimulate both receptor- and nonreceptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol. Pharmacol. 42, 838-845 (1992)
38. C.R. Lupica, A.C. Riegel, A.F. Hoffman, Marijuana and cannabinoid regulation of brain reward circuits. Br. J. Pharmacol. 143, 227-234 (2004)
39. M.G. Bossong, B.N. van Berckel, R. Boellaard, L. Zuurman, R.C. Schuit, A.D. Windhorst, J.M.A. van Gerven, N.F. Ramsey, A.A. Lammertsma, R.S. Kahn, Delta 9tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacol 34, 759-766 (2009)
40. L.N. Voruganti, P. Slomka, P. Zabel, A. Mattar, A.G. Awad, Cannabis induced dopamine release:an invivo SPECT study. Psychiatry Res. 107, 173-177 (2001)
41. P.R. Stokes, M.A. Mehta, H.V. Curran, G. Breen, P.M. Grasby, Can recreational doses of THC produce significant dopamine release in the human striatum? NeuroImage. 48, 186-190 (2009)
42. E. Barkus, P.D. Morrison, D. Vuletic, J.C. Dickson, P.J. Ell, L.S. Pilowsky, R. Brenneisen, D.W. Holt, J. Powell, S. Kapur, R.M. Murray, Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J. Psychopharmacol. 25, 1462-1468 (2011)
43. M. Vallee, Pregnenolone can protect the brain from cannabis intoxication. Science 343, 94-98 (2014)
44. M.A. Huestis, D.A. Gorelick, S.J. Heishman, K.L. Peston, R.A. Nelson, E.T. Moolchan, R.A. Frank, Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry 58, 322-328 (2001)
45. M.R. Elphick, M. Egertova, The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci. 356, 381-408 (2001)
46. R.G. Pertwee, The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids:delta9tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199-215 (2008)
47. M. Kathmann, K. Flau, A. Redmer, C. Trankle, E. Schlicker, Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg's Archiv. Pharmacol. 372, 354-361 (2006)
48. E.H. Chartoff, H.S. Connery, It's MORe exciting than mu:crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. Front Pharmacol. 5, 116 (2014)
49. J.C. Garriott, L.J. King, R.B. Forney, F.W. Hughes, Effects of some tetrahydrocannabinols on hexobarbital sleeping time and amphetamine induced hyperactivity in mice. Life Sci. 6, 2119-2128 (1967)
50. J. Howes, P. Osgood, The effect of delta9-tetrahydrocannabinol on the uptake and release of 14Cdopamine from crude striatal synaptosoma; preparations. Neuropharmacol. 13, 1109-1114 (1974)
51. J. Fernandez-Ruiz, M. Hernandez, J.A. Ramos, Cannabinoiddopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16, 72-91 (2010)
52. M. Herkenham, A.B. Lynn, B.R. Decosta, E.K. Richfield, Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547, 267-274 (1991)
53. M.A. De Luca, V. Valentini, Z. Bimpisidis, F. Cacciapaglia, P. Caboni, G. Di Chiara, Endocannabinoid 2-arachidonoylglycerol self-administration by SpragueDawley rats and stimulation of in vivo dopamine transmission in the nucleus accumbens shell. Front. Psychiatry. 5, 140 (2014)
54. A.S. Bloom, W.L. Dewey, A comparison of some pharmacological actions of morphine and delta 9 tetrahydrocannabinol in the mouse. Psychopharmacol. 57, 243-248 (1978)
55. M. Hershkowitz, H. Szechtman, Pretreatment with delta 1-tetrahydrocannabinol and psychoactive drugs:effects on uptake of biogenic amines and on behavior. Euro. J. Pharmacol. 59, 267-276 (1979)
56. M.K. Poddar, W.L. Dewey, Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J. Pharmacol. Exp. Ther. 214, 63-67 (1980)
57. L. Maitre, M. Staehelin, H.J. Bein, Effect of an extract of cannabis and of some cannabinols on catecholamine metabolism in rat brain and heart. Agents Actions 1, 136-143 (1970)
58. A.S. Bloom, K.M. Johnson, W.L. Dewey, The effects of cannabinoids on body temperature and brain catecholamine synthesis. Res. Commun. Chem. Pathol. Pharmacol. 20, 51-57 (1978)
59. J. Romero, R. Demiguel, E. Garciapalomero, J.J. Fernandezruiz, J.A. Ramos, Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor-ligand, on extrapyramidal function. Brain Res. 694, 223-232 (1995)
60. B. Bosier, G.G. Muccioli, B. Mertens, S. Sarre, Y. Michotte, D.M. Lambert, E. Hermans, Differential modulations of striatal tyrosine hydroxylase and dopamine metabolism by cannabinoid agonists as evidence for functional selectivity in vivo. Neuropharmacol. 62, 2328-2336 (2012)
61. M. Navarro, J.J. Fernandez-Ruiz, R. de Miguel, M.L. Hernandez, M. Cebeira, J.A. Ramos, An acute dose of delta9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behav. Brain Res. 57, 37-46 (1993)
62. S.F. Ali, G.D. Newport, A.C. Scallet, M.G. Paule, J.R. Bailey, W. Slikker Jr., Chronic marijuana smoke exposure in the rhesus monkey. IV:neurochemical effects and comparison to acute and chronic exposure to delta-9-tetrahydrocannabinol (THC) in rats. Pharmacol. Biochem. Behav. 40, 677-682 (1991)
63. M. Navarro, J.J. Fernandez-Ruiz, R. de Miguel, M.L. Hernandez, M. Cebeira, J.A. Ramos, Motor disturbances induced by an acute dose of DELTA9-tetrahydrocannabinol:possible involvement of nigrostriatal dopaminergic alterations. Pharmacol. Biochem. Behav. 45, 291-298 (1993)
64. F.R. Defonseca, J.J. Fernandez-Ruiz, L.L. Murphy, M. Cebeira, R.W. Steger, A. Bartke, J.A. Ramos, acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat-brain areas. Pharmacol. Biochem. Behav. 42, 269-275 (1992)
65. N.D. Volkow, H. Gillespie, N. Mullani, L. Tancredi, C. Grant, A. Valentine, L. Hollister, Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res. 67, 29-38 (1996)
66. R.G. Pertwee, R.A. Ross, Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids. 66, 101-121 (2002)
67. S.J. Borgwardt, P. Allen, S. Bhattacharyya, P. Fusar-Poli, J.A. Crippa, M.L. Seal, V. Fraccaro, Z. Atakan, R. Martin-Santos, C. O'Carroll, K. Rubia, P.K. McGuire, Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol:effects during response inhibition. Biol. psychiatry. 64, 966-973 (2008)
68. S. Bhattacharyya, P.D. Morrison, P. Fusar-Poli, R. Martin-Santos, S. Borgwardt, T. Winton-Brown, C. Nosarti, C.M. O'Carroll, M. Seal, P. Allen, M.A. Mehta, J.M. Stone, N. Tunstall, V. Giampietro, S. Kapur, R.M. Murray, A.W. Zuardi, J.A. Crippa, Z. Atakan, P.K. McGuire, Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacol 35, 764-774 (2010)
69. H.H. van Hell, G. Jager, M.G. Bossong, A. Brouwer, J.M. Jansma, L. Zuurman, J. van Gerven, R.S. Kahn, N.F. Ramsey, Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacol. 219, 981-990 (2012)
70. A.W. Zuardi, Cannabidiol:from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 30, 271-280 (2008)
71. R. Mechoulam, A.W. Zuardi, F.P. Kapczinski, J.E.C. Hallak, F.S. Guimaraes, J.A.S. Crippa, A. Breuer, Fluorinated CBD Compounds, Compositions and Uses Thereof. Pub. No.:WO/2014/108899. International Application No.:PCT/IL2014/050023. (2014)
72. R. Adams, M. Hunt, J.H. Clark, Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J. Am. Chem. Soc. 62, 196-200 (1940)
73. E.A. Carlini, M. Santos, U. Claussen, D. Bieniek, F. Korte, Structure activity relationship of four tetrahydrocannabinols and the pharmacological activity of five semi-purified extracts of Cannabis sativa. Psychopharmacol. 18, 82-93 (1970)
74. I.G. Karniol, E.A. Carlini, The content of (-) 9-trans-tetrahydrocannabinol (9-thc) does not explain all biological activity of some Brazilian marihuana samples. J. Pharm. Pharmacol. 24, 833-834 (1972)
75. P. Seeman, M. Chau-Wong, J. Tedesco, K. Wong, Brain receptors for antipsychotic drugs and dopamine:direct binding assays. Proc. Natl. Acad. Sci. U. S. A. 72, 4376-4380 (1975)
76. P. Seeman, All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neurosci. Ther. 17, 118-132 (2011)
77. L. Davenport, Cannabis compound may augment antipsychotic meds. Available at www.medscape.com/viewarticle/862312 (accessed on 9 May 2016)
78. F.M. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C.W. Gerth, C. Hoyer, J. Klosterkotter, M. Hellmich, D. Koethe, Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry. 2, e94 (2012)
79. A.W. Zuardi, J.A. Rodrigues, J.M. Cunha, Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacol. (Berl) 104, 260-264 (1991)
80. F.A. Moreira, F.S. Guimarães, Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur. J. Pharmacol. 512, 199-205 (2005)
81. V.M. Guimarães, A.W. Zuardi, E.A. Del Bel, F.S. Guimarães, Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci. 75, 633-638 (2004)
82. F. Petitet, B. Jeantaud, M. Reibaud, A. Imperato, M.C. Dubroeucq, Complex pharmacology of natural cannabinoids:evidence for partial agonist activity of delta9tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63, PL1-PL6 (1998)
83. L.E. Long, D.T. Malone, D.A. Taylor, Cannabidiol reverses MK-801 induced disruption of prepulse inhibition in mice. Neuropsychopharmacol. 31, 795-803 (2006)
84. A. Gururajan, D.A. Taylor, D.T. Malone, Effect of cannabidiol in a MK801-rodent model of aspects of Schizophrenia. Behav. Brain Res. 222, 299-308 (2011)
85. H. Alimohamad, L. Sutton, J. Mouyal, N. Rajakumar, W.J. Rushlow, The effects of antipsychotics on B-catenin, glycogen synthase kinase-3 and disheveled in the ventral midbrain of rats. J. Neurochem. 95, 513-525 (2005)
86. L.P. Sutton, D. Honardoust, J. Mouyal, N. Rajakumar, W.J. Rushlow, Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3. J. Neurochem. 102, 153-169 (2007)
87. Z. Freyberg, S.J. Ferrando, J.A. Javitch, Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am. J. Psychiatry. 167, 388-396 (2010)
88. J. Renard, M. Loureiro, L.G. Rosen, J. Zunder, C. de Oliveira, S. Schmid, W.J. Rushlow, S.R. Laviolette, Cannabidiol counteracts amphetamine-induced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR/p70S6 kinase signaling pathway. J. Neurosci. 36, 5160-5169 (2016)
89. A. Englund, P.D. Morrison, J. Nottage, D. Hague, F. Kane, S. Bonaccorso, J.M. Stone, A. Reichenberg, R. Brenneisen, D. Holt, A. Feilding, L. Walker, R.M. Murray, S. Kapur, Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampaldependent memory impairment. J. Psychopharmacol. 27, 19-27 (2013)
90. M. Di Forti, J.M. Lappin, R.M. Murray, Risk factors for schizophrenia-all roads lead to dopamine. Eur. Neuropsychopharmacol. 17(Suppl 2), S101-S107 (2007)
91. S. Luzi, P.D. Morrison, J. Powell, M. di Forti, R.M. Murray, What is the mechanism whereby cannabis use increases risk of psychosis? Neurotox. Res. 14, 105-112 (2008)
92. M.D. Antion, M. Merhav, C.A. Hoeffer, G. Reis, S.C. Kozma, G. Thomas, E.M. Schuman, K. Rosenblum, E. Klann, Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity. Learn. Mem. 15, 29-38 (2008)
93. C.A. Hoeffer, E. Klann, mTOR signaling:at the crossroads of plasticity, memory and disease. Trends Neurosci. 33, 67-75 (2010)
94. C.S. Jernigan, D.B. Goswami, M.C. Austin, A.H. Iyo, A. Chandran, C.A. Stockmeier, B. Karolewicz, The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuropsycho. Pharmacol. Biol. Psychiatry. 35, 1774-1779 (2011)
95. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X.Y. Li, G. Aghajanian, R.S. Duman, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964 (2010)
96. P.W. Kalivas, P. Duffy, Time course of extracellular dopamine and behavioral sensitization to cocaine:Ⅱ dopamine perikarya. J. Neurosci. 13, 276-284 (1993)
97. X.Y. Lu, M.B. Ghasemzadeh, P.W. Kalivas, Expression of D1 receptor, D2receptor, substance Pandenkephalin messenger RNAs in the neurons projecting from the nucleus accumbens. Neuroscience 82, 767-780 (1998)
98. I. Usuda, K. Tanaka, T. Chiba, Efferent projections of the nucleus accumbens in the rat with special reference to subdivision of the nucleus:biotinylated dextranamine study. Brain Res. 797, 73-93 (1998)
99. D.B. Carr, S.R. Sesack, Projections from the rat prefrontal cortex to the ventral tegmental area:target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J. Neurosci. 20, 3864-3873 (2000)
100. A. Tripathi, L. Prensa, C. Cebrián, E. Mengual, Axonal branching patterns of nucleus accumbens neurons in the rat. J. Comp. Neurol. 18, 4649-4673 (2010)
101. Y. Xia, J.R. Driscoll, L. Wilbrecht, E.B. Margolis, H.L. Fields, G.O. Hjelmstad, Nucleus accumbens medium spiny neurons target nondopaminergic neurons in the ventral tegmental area. J. Neurosci. 31, 7811-7816 (2011)
102. L.C. Einhorn, P.A. Johansen, F.J. White, Electrophysiological effects of cocaine in the mesoaccumbens dopamine system:studies in the ventral tegmental area. J. Neurosci. 8, 100-112 (1988)
103. S. Rahman, W.J. McBride, Feedback control of mesolimbic somatodendritic dopamine release in rat brain. J. Neurochem. 74, 684-692 (2000)
104. M. Pratt, A. Stevens, M. Thuku, C. Butler, B. Skidmore, L.S. Wieland, M. Clemons, S. Kanji, B. Hutton, Benefits and harms of medical cannabis:a scoping review of systematic reviews. Systemat. Rev. 8, 320 (2019)
105. S.J. Watson, J.A. Benson, J.E. Joy, Marijuana and medicine:assessing the science base:a summary of the 1999, Institute of Medicine report. Arch. Gen. Psychiatry. 57, 547-552 (2000)
106. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice & Committee on the Health Effects of Marijuana:An Evidence Review and Research Agenda. The health effects of cannabis and cannabinoids:the current state of evidence and recommendations for research. US:National Academies Press; (2017)
107. Number of Legal Medical Marijuana Patients-Medical Marijuana-ProCon. org. https://medicalmarijuana.procon.org/view.resource.php? resourceID=005 889
108. J. Miller, Number of Canadians buying legal medical marijuana triples in past year, Ottawa Citizen. https://ottawacitizen.com/news/local-news/number-of-canadians-buying-legal-medicalmarijuana-triples-in-just-one-year (2016)
109. W. Häuser, F. Petzke, M.A. Fitzcharles, Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management-an overview of systematic reviews. Eur. J. Pain Lond. Engl. 22, 455-470 (2018)
110. S. Herzog, M. Shanahan, P. Grimison, A. Tran, N. Wong, N. Lintzeris, J. Simes, M. Stockler, R.L. Morton, Systematic review of the costs and benefits of prescribed cannabis-based medicines for the management of chronic illness:lessons from multiple sclerosis. Pharmacoeconom. 36, 67-78 (2017)
111. R. Pavlovic, G. Nenna, L. Calvi, S. Panseri, G. Borgonovo, L. Giupponi, G. Cannazza, A. Giorgi, Quality traits of "cannabidiol oils":cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules 23, 1230 (2018)
112. A. Hazekamp, The trouble with CBD oil. Med. Cannabis Cannabinoids 1, 65-72 (2018)
113. O. Devinsky, A.D. Patel, E.A. Thiele, M.H. Wong, R. Appleton, C.L. Harden, S. Greenwood, G. Morrison, K. Sommerville, GWPCARE1 Part A study group. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurol. 90, e1204-e1211 (2018)
114. S. Shannon, J. Opila-Lehman, Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder:a case report. Perm. J. Fall. 20, 16-005 (2016)
115. S. Shannon, J. Opila-Lehman, Cannabidiol oil for decreasing addictive use of marijuana:a case report. Integr. Med. (Encinitas) 14, 31-35 (2015)
116. P.F. Whiting, R.F. Wolff, S. Deshpande, M.D. Nisio, S. Duffy, A.V. Harnandez, J.C. Keurentjes, S. Lang, K. Misso, S. Ryder, S. Schmidlkofer, M. Westwood, J. Kleijnen, Cannabinoids for medical use:a systematic review and meta-analysis. JAMA 313, 2456-2473 (2015)
117. National Institute for Health and Care Excellence. Do Not Do Recommendations:Sativex to treat spasticity in people with MS because it is not a cost effective treatment. 2014. https://www.nice.org.uk/donotdo/do-not-offer-sativex-to-treat-spasticity-inpeople-withms-because-it-is-not-a-cost-effective-treatment.
118. M. Colizzi, S. Bhattacharyya, Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr. Addict. Rep. 4, 62-74 (2017) |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
